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Objective: The purpose of this paper is to present an overview of the interrelation-
ship between hormones, nutrition, and wound healing. Methods: The data on various
hormones and their effects on specific elements of nutrition and wound healing are re-
viewed. Results: The key anabolic hormones are human growth hormone, insulin-like
growth factor-1, insulin, and testosterone and its analogs. Although each has specific
metabolic actions, there is also a very important hormone-hormone interaction. A defi-
ciency of these hormones occurs in acute and chronic catabolic states, resulting in lean
mass loss and impairing the healing process. Conclusion: There is a well-recognized
interrelationshipbetweenhormones,nutrition,andwoundhealing.Theanabolicprocess
ofproteinsynthesis,withnewtissueformation,requirestheactionofanabolichormones.
Exogenous administration of these agents has been shown to maintain or increase lean
body mass as well as directly stimulate the healing process through their anabolic and
anticatabolic actions.
There are a number of key hormones involved with energy production, anabolism
or protein synthesis, and catabolism or protein breakdown. The balance of anabolic and
catabolichormonesaffectswoundhealingbothindirectlybythestatusofoverallnetprotein
synthesis and directly by improving the wound healing process.1–4 A decrease in normal
anabolic hormone activity and an increase in catabolic hormone activity occurs with the
“stress response” to injury and also with aging and chronic illness.
Thealteredhormonalenvironmentcanleadtobothasignificantincreaseincatabolism,
withnettissuebreakdown,andadecreaseintheoverallanabolicactivityrequiredtopreserve
lean mass and maintain the healing process. The stress response to injury also produces an
alteration in the normally protective protein sparing as seen in the normal and starved states
aimed at preserving lean body mass.
The metabolic pathways, which generate energy to meet daily demands and for new
proteinsynthesis,areverytightlyregulatedinnormalorstarvedhumans.5–8 Macronutrients
in the form of fat and carbohydrates are channeled into production of energy,5–11 while the
majority of protein consumed is used for protein synthesis, restoring and maintaining lean
bodymass.Leanmass,themetabolicallyactivebodycompartmentcontainingalltheprotein
plus water, in the body includes muscle, skin, and the immune system, all of which are
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Table 1. Hormonal response to stress and starvation∗
Starvation “Stress”
Catechols ↓↑ ↑
Cortisol ↓↑ ↑
Insulin ↓↑
Glucagon ↓↑
Growth hormone ↑↑ ↓
Testosterone ↓↓
∗The hormonal response to starvation is compared to that for “stress.” With starvation, an adaptive hormonal response is
present, preserving lean mass and energy, while a maladaptive catabolic state occurs with the “stress response” activated by
aw ound.
composed of protein. Normally, only 5% of consumed protein is used for energy. However,
if anabolic activity decreases, as with stress or with aging or chronic illness, there is an
escape of protein from the protein synthesis compartment to the energy compartment. Up
to 25% of available protein substrate is burned for energy.3–9,12 A protein deficiency can
occur and with the increased energy demands of a wound, a protein energy malnutrition
can quickly evolve, especially in high-risk groups like the elderly with preexisting lean
mass loss.10,11 Morbidity, especially impaired immunity and impaired healing, is directly
proportional to the degree of lean mass loss.13–15 Impaired healing therefore is the result of
both an inadequate intake of protein substrate and actual shunting of protein substrate away
from the wound to be used instead for the restoration of lost lean mass.
THE RATIONALE FOR HORMONAL MODIFICATION
Itisnowwellrecognizedthatthehormonalenvironment,socriticaltowoundhealing,canbe
beneficiallymodified.1,3,16,17Ingeneral,restorationorimprovementinnetproteinsynthesis,
required in wound healing, is the result of 2 processes. The first is an attenuation of the
catabolichormonalresponsetoinjury.Anyhormonalmanipulationthatdecreasestherateof
catabolismwouldappeartobebeneficialforwoundhealing.Alltheanabolichormoneshave
been shown to have anticortisol activity.1–4 This effect decreases the catabolic response of
cortisolbutdoesnotalteritsprotectiveanti-inflammatoryresponse.Ablockadeofcortisol’s
anti-inflammatory properties could lead to an excessive “autodestructive” inflammatory
process.
The second process is the accentuation of anabolic activity both generally and specific
to the wound. A number of clinical and basic science studies have demonstrated the ability
of exogenous delivery of anabolic hormones to increase net nitrogen retention and overall
proteinsynthesis.Woundhealinghasalsobeenreportedtobeimproved.However,itremains
difficult to sort out how much of the response is a result of an overall systemic anabolic
effect and how much is due to direct effect on wound healing.18,19
There are 4 major anabolic hormones that indirectly or directly affect wound healing.
They are human growth hormone (HGH), insulin-like growth factor-1 (IGF-1), insulin,
and testosterone (and its analogs) (Table 2). As will be described later, each hormone
has a specific mode of action but there are considerable interrelationships among these
4 hormones. In subsequent sections, the individual anabolic hormones will be discussed.
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Table 2. Effects of anabolic hormones
Increased anabolism Direct wound effect
Insulin Yes Unclear
Human growth hormone Yes Unclear
Insulin-like growth factor-1 Yes Yes
Testosterone Tes Unclear
Anabolic
Steroids Yes Yes
It is important to emphasize that for any anabolic hormone to stimulate protein synthesis
adequate calories for energy and protein for substrate must be provided. In the case of the
hypermetabolic state seen in the stress response, a high caloric (30 cal/kg daily) and high
protein (1.5 g/kg daily) intake is necessary.20,21
HUMAN GROWTH HORMONE
Actions
HGH is a potent endogenous anabolic hormone produced by the pituitary gland in daily
doses of 0.5 to 0.8 mg in children and young adults. Growth hormone is a large polypeptide
that contains 2 receptor-binding sites. There are a number of growth hormone–binding
proteins, and growth factor–binding sites are found on a large variety of tissues, especially
liver. The production of HGH decreases rapidly with increasing age. The levels are at their
peak during the growth spurt. Starvation and intense exercise are 2 other potent stimuli
while acute or chronic injury or illness suppress HGH release, especially in the elderly.22–27
The amino acids glutamine and arginine, when given in large doses, have also been shown
to increase HGH release.
HGHhasanumberofmetaboliceffects.Themostprominentisitsanaboliceffect.HGH
increases the influx of amino acids into the cell and decreases the efflux. Cell proliferation
is accentuated as is overall protein synthesis and new tissue growth. HGH also stimulates
IGF-1 production by the liver, and some of the anabolism seen with HGH is that produced
by IGF-1, another anabolic agent.26–30 Other effects, listed in Tables 3 and 4, include its
effects on glucose and fat metabolism.
The effect on increasing fat metabolism is beneficial in that fat is preferentially used
for energy production and amino acids are preserved for use in protein synthesis.
Table 3. Anabolic effects of human growth hormone∗
• Increases cell uptake of amino acids
• Accelerates nucleic acid translation and transcription
• Increases nitrogen retention
• Increases protein synthesis
• Decreases cortisol receptor activity
• Increases release of insulin-like growth factor-1
• Increases insulin requirements
∗Levels decrease with “stress” and with increasing age.
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Table 4. Metabolic effects of human growth hormone∗
• Increases hydrolysis of fat to fatty acids
• Increases fat oxidation for fuel, decreasing fat stores
• Increases metabolic rate (10%–15%)
• Produces insulin resistance, often leading to hyperglycemia
• Causes some initial fluid retention
∗Increased metabolic rate and hyperglycemia are negative effects,
while increased use of fat for fuel is a positive effect.
RecentdataindicatethatinsulinprovidessomeoftheanaboliceffectsofHGHtherapy.
At present, the issue as to the specific anabolic effects attributed to HGH versus IGF-1 and
insulin remains unresolved.
Clinical results of HGH use
Clinicalstudieshaveinlargepartfocusedonthesystemicanabolicandanticatabolicactions
of HGH.31–33 Populations where HGH has been shown to be beneficial include those with
severeburnandtrauma,thosewithHIVinfectionwithwasting,andthefrailelderly(Table5).
In addition, HGH is being used to slow down the aging process. Increases in lean mass,
muscle strength, and immune function have been documented in clinical use. HGH is
approved for use only in short statured children and is an orphan drug when used for
improving protein synthesis. Increased anabolic activity from HGH requires intake of a
high-protein, high-energy diet.
Wound healing effect
As to its direct wound healing effects, skin is a target tissue for HGH, both directly through
HGH receptors on the surface of epidermal cells and indirectly through the action of IGF-
1.30,34 ExogenouslyadministeredHGHhasbeenshowntoincreaseskinthicknessinnormal
humans.35
Other effects on the wound include increased rate of re-epithelialization of skin graft
donor sites in adults and children with severe burns or trauma (Table 6).36–38
In addition, HGH has been shown to increase wound collagen content, granulation
tissue and wound tensile strength, and the local production of IGF-1 by fibroblasts. These
data are mainly derived from animal studies.39–41
Table 5. Clinical uses of human growth hormone∗
• Presence of severe catabolism from injury or illness
• Malnourished patients with a superimposed catabolic illness
• Acute loss of >15% lean body mass (muscle)
• Large wounds (burns) or wounds with poor healing
• Immunodeficiency states (AIDS), especially with weight loss
• Anti-aging treatment regimens
∗Beneficial effects of human growth hormone on net anabolism have
been reported for each of these patient populations.
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Table 6. Wound healing effects of human growth hormone∗
• Increases re-epithelialization rate of donor sites
• Increases wound collagen content
• Increases granulation tissue
• Increases wound tensile strength
∗The first 2 effects have been noted in humans while the last 2 effects have
been described in animals.
Complications
Significant complications can occur with the use of HGH. The anti-insulin effects are
problematic in that glucose is less efficiently used for fuel and increased plasma glucose
levels are known to be deleterious.
Increased insulin requirements occur. Complications are listed in Table 7.42,43 It is
important to also point out the findings of a multicenter European study of critically ill
patients receiving HGH. In this study of mainly critically ill postoperative cardiac patients,
mortality was 2-fold greater in those treated with HGH compared to those treated with
placebo.43
Summary
In summary, HGH used in conjunction with adequate nutrition and protein intake clearly
resultsinincreasedanabolicactivityandwillpositivelyimpactwoundhealingbyincreasing
net protein synthesis in catabolic states. There is some data that HGH can directly improve
wound healing. However, the impact of IGF-1 and insulin on the effects of HGH remains
undefined.
INSULIN-LIKE GROWTH FACTOR-1
Actions
IGF-1 is a large polypeptide that has hormone like properties.44–46 IGF-1, also known as
somatomedin-C, has metabolic and anabolic properties very similar to those of insulin.
Although produced by a variety of wound cells, such as fibroblasts and platelets,
the main source of production is liver where its synthesis is initiated by HGH. The
IGF receptor is expressed in many different tissues and the active peptide is bound in
Table 7. Potential problems or issues related to human
growth hormone treatment
• Insulin resistance (hyperglycemia)
• Increased insulin demands
• Fluid retention (usually self-limiting)
• Hypercalcemia (uncommon with short-term use)
• Increase in metabolic rate
• Must be given parenterally
∗Hyperglycemia and increased insulin requirements are the most common
problems.
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Table 8. Characteristics of insulin-like growth factor-1
• Levels decrease with severe injury, severe trauma, infection, and increasing age
• Production dependent on human growth hormone release
• Production requires the presence of androgens
• Actions much like those of insulin
• Can produce hypoglycemia
• Increases protein synthesis and attenuates stress-induced hypermetabolism
plasma by IGF-binding proteins. IGF increases systemic nitrogen retention and protein
synthesis.47–49 However, its anabolic activity is difficult to distinguish from that of HGH
as HGH needs to be present in order for IGF-1 to be produced and to have anabolic
actions. The combination of HGH and IGF-1 delivery results in a synergistic anabolic
effect.49
The effects of HGH on wound healing are also considered to be due in part to
IGF-1.49 IGF-1 production is also dependent on normal levels of circulating androgens.45
Thereisthereforeacloseinterrelationshipbetweenalloftheanabolichormones.IGF-1lev-
els decrease with aging and also with a major insult such as trauma or sepsis. The decrease
in IGF-1 levels increases the net nitrogen losses caused by wounds.
Clinical results of IGF-1 use
Properties of IGF-1 are summarized in Table 8. Its metabolic properties include increased
protein synthesis, decrease in blood glucose, and attenuation of stress-induced hyperme-
tabolism, the latter 2 properties being quite different from those of HGH.50–52 The attenua-
tionofstress-inducedhypermetabolismisaveryfavorablepropertyofIGF-1.Clinicaltrials,
using an IGF-1 infusion, have focused on demonstrating increased anabolic activity.53,54
Increased protein synthesis and nitrogen retention has been reported in burns, head injury,
and HIV-induced catabolic states.
Wound healing effect
The wound healing effects of IGF-1 are described in Table 9.31,32,55,56 IGF-1 is considered
to be a wound healing stimulant, increasing cell proliferation and collagen synthesis. In
addition, IGF-1 infusion has been shown to reverse diabetes and corticosteroid-induced
impairment in wound healing. It is important to point out that these properties have largely
been reported in animal studies. However, the increase in overall anabolism should benefit
aw ound.
Table 9. Wound healing and insulin-like growth factor-1
• General wound healing stimulant
Increases cell replication
Increases epithelialization rate
Increases angiogenesis rate
• Reverses both diabetes and corticosteroid-induced impaired healing
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Table 10. Anabolic effects of insulin∗
• Increases cell amino acid influx
• Decreases amino acid reflux
• Increases muscle protein synthesis and decreases degradation
• Increases skin wound protein content
• Increases carbohydrate utilization
∗The anabolic effect decreases with age.
Complications
Hypoglycemiaisthemaincomplication.IGF-1ingeneralappearstohavefewersideeffects
thandoHGH.However,itisusuallygivenasacontinuousinfusionbecauseofitsveryshort
half-life. This factor limits its clinical usefulness.
Summary
IGF-1 used in conjunction with adequate nutrition significantly increases net anabolic ac-
tivity. Its direct effect on wound healing is less clear. The attenuation of stress-induced
hypermetabolism is a significant advantage. Clinical use is hampered by the need for a
continuous infusion.
INSULIN
Actions
The hormone insulin is known to have anabolic activities in addition to its effect on glucose
andfatmetabolism.57 Inacatabolicstate,exogenousinsulinadministrationhasbeenshown
to decrease proteolysis in addition to increasing protein synthesis.33,39–41
The anabolic activity appears to mainly affect the muscle and skin protein in the lean
body mass compartment (Table 10). An increase in circulating amino acids produced by
wound amino acid intake increases the anabolic and anticatabolic effect in both normal
humans and populations in a catabolic state.39–41,58
Clinical results of insulin use
A number of clinical trials, mainly in burn patients (Table 11), have demonstrated the
stimulation of protein synthesis and decreased protein degradation and net nitrogen uptake,
especiallyinskeletalmuscle.58–63 Anincreaseinanabolicactivityisalsoevidentindiabetic
patients who are provided more insulin. The positive effect of insulin on protein synthesis
Table 11. Clinical studies on insulin∗
• Stimulates muscle protein synthesis in catabolic burn patients
• Stimulates muscle protein synthesis in normal humans
• Decreases protein breakdown in catabolic patients
• Increases the re-epithelialization rate of donor sites in burn patients
∗There are clear anabolic effects.
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decreases with aging.64 This response is different from that of HGH and anabolic steroids
where age does not appear to blunt the anabolic response.
Wound healing effect
There is less data on the actions of insulin on wound healing over and above its systemic
anabolic effect.61,65–67 Increases in skin protein content have been demonstrated with a
chronicinsulininfusion.Increasedre-epithelializationofskingraftdonorsiteswasreported
in one clinical trial in burn patients. Several animal studies have demonstrated increased
collagen production with insulin, and increasing insulin administration to diabetic mice
improved all phases of healing. However, the effects of insulin on wound healing have not
been well studied in humans.
Complications
The main complication is hypoglycemia. There does not appear to be any fluid retention or
hypermetabolism with its use.
Summary
In summary, hyperinsulinemia in catabolic patients and in normal humans increases net
protein synthesis and decreases protein breakdown. An infusion of glucose is required to
avoid hypoglycemia. In turn, inadequate insulin intake in diabetic patients leads to progres-
sive lean mass loss and hyperglycemia appears to accentuate the nitrogen loss. Although
some positive data are present on insulin improving healing, the data are limited.
TESTOSTERONE
Actions
Testosterone, whose basic structure is a steroid ring, is a natural endogenous androgen.68–70
It is synthesized primarily in the Leydig cells of the testes in men and by the ovaries and
adrenal glands in women. Healthy adult men produce 3 to 10 mg of testosterone a day,
yielding plasma concentrations ranging from 300 to 1000 µg/dL.71–73 It acts on the cells’
androgenic receptors found mainly in skin, muscle, and male sex glands. It has both andro-
genic or masculinizing properties and anabolic properties. Androgenic effects are present
to some degree in all anabolic steroids. Androgenic effects include development of male
sex glands, determination of male hair growth pattern, increased libido, and assertiveness
(Table 12). Most testosterone analogs or anabolic steroids have androgenic properties much
lower than those of testosterone itself.57,74,75 The anabolic properties were defined in the
1930s. These include an increase in muscle size, synthesis, and strength. Increased skin
thickness has also been noted with administration of testosterone to hypogonadal men. The
importance of testosterone is evidenced by the complications seen with low testosterone
levels, which include sarcopenia or lost lean mass, increased rate of development of osteo-
porosis, anemia, thinning of skin and weakness, and impaired wound healing (Tables 13
and 14).71,76,77
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Table 12. Testosterone’s characteristics∗
• Endogenous anabolic hormone
• Produced mainly by the testes in men and the adrenal gland in woman
• Acts on androgenic receptors found mainly in muscle, skin, and sex glands
• Has modest anabolic activity compared to its analogs
• Androgenic activity includes male sex gland development, male hair growth pattern
determination, mood
• Rapidly metabolized by the liver
• Levels decrease with increasing age
• Levels decrease with injury/infection
• Decreased testosterone causes lean mass loss in normal and injured man
∗Decreasing testosterone levels with age and illness will result in a decrease in anabolic activity.
The native molecule was first used in the 1950s to correct a debilitated state, cor-
rect anemia, and increase calcium deposition in bones as well as to treat hypogonadal
states .68–70,76,77 The testosterone molecule is rapidly metabolized by the liver such that the
half-life is only about 20 minutes. Adjustments were made to the molecule to increase its
time of action, the most popular being testosterone enthanate.
Decreased production, leading to a hypogonadal state, occurs with increasing age as
well as with injury or infection, especially severe trauma and chronic illness such as HIV
infection and chronic wounds.
Ah ypogonadal state is seen in many patient populations, including those in an acute
severeinjurystate,thosewithinfectionormorechronicstatessuchasaging,andthosewith
chronic obstructive pulmonary disease and other chronic illnesses .71,72,76
Clinical results of testosterone use
Testosterone administration is used mainly to correct a hypogonadal state, while testos-
terone analogs, which have a much greater anabolic activity, are used to increase anabolism
(Table 14).70–74,76–78Clinical studies have demonstrated a significant increase in net pro-
tein synthesis, especially in muscle and skin, with high doses of testosterone delivered
parenterally.74,75
Wound healing effect
Itisclearthattestosteroneisneededforthewoundhealingprocesssincedecreasedlevelsim-
pede healing.57,79,80 Adequate testosterone levels are required for IGF-1 production, IGF-1
beingawoundhealingagent.However,thereisnogooddatathatanincreaseintestosterone
levelsabovenormalimproveswoundhealing.Thisisnotthecasewithanumberofanabolic
Table 13. Effectofdecreasedtestosterone(thehypogonadal
state)
• Lean mass loss
• Thinning of skin
• Increasing fat mass
• Impaired wound healing
• Decrease in physical and psychological masculinizing properties
• Osteoporosis
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Table 14. Clinical effects of testosterone administration∗
• Correction of the androgenic/anabolic deficiency of a hypogonadal state
• Increased anabolism and muscle synthesis in the elderly
• Increased lean mass synthesis in normal men
• Decreased bone loss
• Androgenic side effects
∗Androgenic or masculinizing effects will develop with exogenous testosterone use.
steroids that have been shown to increase the rate of wound healing even in the absence of
hypogonadism. These agents will be discussed next.
Complications
The major complications are the androgenic side effects. Some fluid retention has been
reported with high doses. A decrease in high-density lipoproteins has also been reported
with the use of large doses.
Summary
Testosterone is a necessary androgen for maintaining lean mass and wound healing. A
deficiency leads to catabolism and impaired healing. The use of large doses exogenously
increases net protein synthesis, but a direct effect on wound healing has not yet been
demonstrated.
ANABOLIC STEROIDS
Actions
Anabolic steroids refer to the class of drugs produced by modification of
testosterone.68–70,76,77 Thesedrugsweredevelopedinordertotakeclinicaladvantageofthe
anabolic effects of testosterone while decreasing androgenic side effects of the naturally
occurring molecule. Modifications in the steroid ring were made because of the short half-
life of testosterone and its masculinizing properties. Modifications included a 17α methyl
derivative for oral use and a 17β ester configuration for parenteral use. These changes
markedly increased its half-life and decreased its androgenic properties (Table 15).
Table 15. Anabolic steroids (history)
• All are testosterone derivatives
• Anabolic properties noted in the 1940s
• Androgen receptors found in cytosol (1960s)
• Attempt to increase anabolism (use of anabolic to androgenic ratio to judge new drugs [1960 to present])
• Derivatives
Oral are 17α methyl
Parenteral are 17β esters
• Most cleared by the liver (concern for hepatotoxicity)
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Table 16. Anabolic activity of 17 methyl derivatives∗
Agent Androgenic anabolic activity Indications Hepatotoxicity
Testosterone 1:1 Hypogonadism
Nandrolone 1:4 Anemia Moderate to severe
Oxymetholone 1:3 Anemia Severe
Oxandrolone 1:3–1.13 Loss of body weight Mild, rare
from injury or infection
∗The anabolic activity relative to androgenic activity is shown for the Food and Drug Administration–approved anabolic
steroids. Oxandrolone has the greatest anabolic activity and the least androgenic activity and is approved for restoration of
lean body mass.
The mechanisms of action of testosterone analogs are also through activation of the
androgenic receptors, which are found in highest concentration in myocytes and skin fi-
broblasts. Some populations of epithelial cells also contain these receptors. Androgenic
receptors were first isolated in the 1960s.68–70
Stimulation leads to a decrease in efflux of amino acids and an increase in influx into
the cell. Activation of intracellular DNA and DNA polymerase also occurs with androgenic
receptor stimulation. A decrease in fat mass is also seen because of the preferential use of
fat for fuel. There are no metabolic effects on glucose production.
All anabolic steroids increase overall protein synthesis and new tissue formation,
evidenced by an increase in skin thickness and muscle formation71,72 All these agents also
have anticatabolic activity, decreasing the protein degradation caused by cortisol and other
catabolic stimuli.73
In addition, all anabolic steroids also have androgenic or masculinizing effects.
Thequalityofatestosteroneanalogisdeterminedbytheratioofandrogenictoanabolic
activity,thelowerthebetter.Alowvalueindicatesverylittlemasculinizingeffectscompared
to a very potent anabolic effect (Table 16).
The anabolic steroid oxandrolone also happens to have the greatest anabolic and least
androgenic side effects in the class of anabolic steroids.78 It is the only steroid in which a
carbonatomwithinthephenanthrenenucleushasbeenreplacedbyanotherelement,namely
oxygen.Inaddition,oxandroloneisclearedbythekidneyandnottheliver,sohepatotoxicity
is rare.
Oxandrolone is the only approved anabolic steroid for restoration of lost body weight
and lost lean mass.
Clinical result of anabolic steroids use (effect on lean body mass)
Most of the recent studies on anabolic steroids and lean body mass have used the anabolic
steroid oxandrolone (Table 17).57,74,75,79 Oxandrolone is a 17β-hydroxy-17α-methyl ester
of testosterone and is cleared primarily by the kidney. Hepatotoxicity is minimal, even
at doses higher than the 20 mg/d recommended by the Food and Drug Administration.
Oxandrolone has potent anabolic activity, being up to 13 times that of methyltestosterone.
In addition, its androgenic effect is considerably less than that of testosterone, minimizing
thiscomplicationcommontoothertestosteronederivatives.Theincreasedanabolicactivity
and decreased androgenic (masculinizing) activity markedly increases its clinical value.
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Table 17. Clinical effect of anabolic steroids∗
• Attenuate the catabolic stimulus during the “stress response”
• More rapid restoration of lost lean mass
• Restore normal nutrient partitioning
• Improved healing with restoration of lost lean mass
∗These agents have anabolic effects similar to those of other anabolic
hormones but do not have other metabolic effects on carbohydrates
and fat.
Oxandrolone is given orally, with 99% bioavailability. It is protein-bound in plasma with a
biologic life of 9 hours.
The anabolic steroids, especially oxandrolone, have been successfully used in the
trauma and burn patient population to decrease lean mass loss in the acute phase of injury
as well as more rapidly restore the lost lean mass in the recovery phase.43–46,57,74,75,79,81 A
significant attenuation of catabolism and increase in lean mass have also been reported in
those with HIV infection, in the chronic obstructive pulomonary disease population, and in
thespinalcordinjurypopulation.79,80,82 Thereareseveralstudiesdemonstratinganincrease
in the healing of chronic wounds. However, significant lean mass gains were also present.
It is important to point out that in all of the clinical trials where lean mass gains were
reported, a high-protein diet was used. In most studies, a daily protein intake of 1.2 to
1.5 g/kg was used, 0.8 g/kg being the recommended daily intake in a healthy adult.
Wound healing properties
Theeffectsofanabolicsteroidsonwoundhealingappeartobe,inlargepart,duetoageneral
stimulationofoverallanabolicactivity.However,thereisalsoincreasingevidenceofadirect
stimulation of all phases of wound healing by these agents (Tables 18 and 19).83–87
Falanga et al87 reported a stimulation of collagen synthesis with the anabolic steroid
stanazol. Erlich et al88 reported a 10-fold increase in the messenger RNA for collagen syn-
thesisinahumanfibroblastculturewithoxandrolone.Tenenbaumetal64 reportedincreased
synthesis of bone, collagen, matrix, and epidermis in a wound of the oral cavity stimulated
with oxandrolone. Demling79 reported a marked increase in healing of a cutaneous wound
in rats treated with oxandrolone compared to controls. A 50% increase in wound collagen
as well as a doubling of tensile strength was noted at 3 weeks with oxandrolone. Histology
also revealed more densely packed collagen with more fibroblasts and mononuclear cells.
Anabolic steroids have also been shown to release the transforming growth factor beta by
Table 18. Woundhealingeffects(invitrohu-
man ﬁbroblasts)∗
• StimulatemessengerRNAforcollagensynthesis
• Stimulate collagen synthesis
• Increases release of transforming growth factor
beta
• Downregulation of expression of matrix metal-
loproteinases
∗Fibroblasts have a very dense population of androgenic
receptors.
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Table 19. Wound healing effects (animal
studies)∗
• Increased wound closure (contraction)
• Increased collagen deposition
• Increased re-epithelialization
• Increased angiogenesis
• Increased wound tensile strength
∗All phases of wound healing are stimulated.
human fibroblasts. The mechanism of improved wound healing with the use of anabolic
steroids is not yet defined. Stimulation of androgenic receptors on wound fibroblasts may
well lead to a local release of growth factors.
Complications
In addition to androgenic activity, a number of potential side effects exist for this class of
drugs. Some fluid retention will occur initially but is usually transient.57,71–73,77,78 Liver
toxicity has been reported, ranging from a transient increase in aminotransferases to jaun-
dice, liver failure, and rarely a liver tumor.89 The potential for liver change varies among
anabolic steroids.89 Oxandrolone appears to be the safest. A recent 1-year study in elderly
men given oxandrolone demonstrated only transient increases in aminotransferases.
A change in the lipid profile has been reported.87 Several studies have demonstrated a
decrease in high-density lipoproteins, potentially increasing the risk of atherosclerosis. The
lipid response differs among the drugs in this class.90
Anabolic steroids have been reported to increase the potency of coumadin, and
coumadin dose often has to be decreased. Finally, this class of drugs is contraindicated
in patients with prostate cancer as this tumor is stimulated by androgenic receptors.77,78
Summary
Anabolic steroids are analogs of testosterone modified to increase anabolic and decrease
androgenic side effects. All these agents have been shown to increase lean body mass.
In addition, there appears to be a direct wound healing effect. Side effects include liver
dysfunction. Oxandrolone appears to be the most anabolic and the safest anabolic steroid.
SUMMARY AND FUTURE DIRECTION
Anabolic hormones are necessary to maintain the necessary protein synthesis required for
maintaining lean body mass including wound healing, assuming the presence of adequate
protein intake. However, endogenous levels of these hormones are decreased in acute and
chronic illness and with increasing age, especially in the presence of a large wound.
Thecorroboratingdatafortheuseofanabolichormonesareexcellentformorerapidly
restoring protein synthesis and lean mass with lean mass loss. A high-calorie, high-protein
diet is required.
Since lost lean mass, caused by the stress response, aging, and malnutrition, retards
wound healing, the ideal use of these agents is to more effectively restore anabolic activity.
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All these agents can cause complications, specific to the hormone used, which needs to be
appreciated.
There is also data that indicate a direct wound healing stimulating effect for some of
thesehormones.However,moreclinicaldataneedstobeobtainedbeforearecommendation
can be made to use anabolic hormones to increase the rate of wound healing in the absence
of a catabolic state or in the absence of an existing lean mass loss. Oxandrolone is currently
theagentofchoice,unlesscontraindicatedwiththepresenceofprostatecancer,asthisagent
is safe, easy to administer, and does not have the metabolic side effects of HGH, IGF-1,
and insulin.
Three areas of research and development are indicated at this point. The first area is
to better define the effect of all of these anabolic hormones on the various stages of wound
healing. This information is needed in order to determine the indications for the use of the
available anabolic hormones. It is quite possible that combination therapy would be more
beneficial if it is determined that these agents have different modes of action. The second
area is the development of analogs of anabolic hormones that appear to have the most
beneficial wound healing effects. The analogs would be developed to maximize wound-
healing activity and minimize complications. The third area would be the development of a
topical form of the anabolic hormones that demonstrate the most beneficial wound healing
effects.Thetopicalformwouldprovideadirectwoundhealingbenefitwithoutthepotential
complications of systemic use.
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